Business context and reporting period
The supplied filing is Organovo Holdings, Inc.’s Form 10-K for the fiscal year ended March 31, 2019—not a filing for Vivosim Labs, Inc. or a standalone 2018 fourth quarter. Organovo develops 3D-bioprinted human tissues, including an in vivo liver tissue candidate and in vitro research models, and sells specialized human cells through its Samsara subsidiary.
The filing was signed June 3, 2019. Financial figures below are in U.S. dollars; millions are abbreviated as “M.”
Financial results and liquidity
| Metric | FY ended Mar. 31, 2019 | FY ended Mar. 31, 2018 | Change |
|---|---|---|---|
| Revenue | $3.091M | $4.603M | Down 33% |
| Cost of revenue | $0.482M | $1.030M | Down 53% |
| Gross profit / margin | $2.609M / 84.4% | $3.573M / 77.6% | Margin up 6.8 percentage points |
| Research and development | $14.752M | $17.956M | Down 18% |
| Selling, general and administrative | $15.131M | $20.888M | Down 28% |
| Operating loss | $27.274M | $35.271M | Loss narrowed |
| Net loss | $26.635M | $34.803M | Loss narrowed |
| Net loss per share, basic and diluted | $0.23 | $0.32 | Loss per share narrowed |
| Cash used in operating activities | $20.375M | $28.857M | Use decreased $8.482M |
Revenue comprised $2.333M from products and services, $0.171M from collaborations and licenses, and $0.587M from grants. The filing attributes the revenue decline mainly to fewer liver-tissue testing service contracts and completed collaborations. Product and service revenue fell by about $1.3M; collaboration revenue fell by about $0.2M. The company said the gross-margin improvement reflected lower costs and a higher share of higher-margin primary human cell product sales.
At March 31, 2019, cash and cash equivalents were $36.477M, versus $43.726M a year earlier; working capital was $34.837M, versus $42.102M. Total assets were $40.623M, total liabilities $4.325M, and stockholders’ equity $36.298M. The filing reports no material debt balance; its disclosed contractual obligations were operating leases of $6.273M. The company reported an accumulated deficit of $260.755M.
Financing activities provided $13.154M, including approximately $13.2M in net proceeds from at-the-market common-stock sales. The company said its cash resources and operating plan were sufficient for at least the next 12 months, while also stating that substantial additional capital would be needed for therapeutic development. It warned that future financing may be unavailable or dilutive.
Material changes, outlook, and risks
- Lead program delay and uncertainty: In May 2019, after the fiscal year-end, Organovo disclosed that larger animal studies continued to show meaningful reductions in A1AT-related toxic globules over three months, but tissue duration and functionality were shorter than in pilot studies. It planned manufacturing optimization and further preclinical work extending into calendar 2020. The candidate had not entered clinical trials, and the company had no approved therapeutic products.
- Strategic focus: Management said it would prioritize in vivo liver development and be more selective in pursuing in vitro collaborations. Longer-term goals included an IND submission and Phase I studies, further NASH disease-modeling work, growth in Samsara cell-product sales, and eventual commercial operational breakeven. These are objectives, not financial guidance; the filing provides no revenue or earnings forecast.
- Operating losses and funding: Organovo had a history of losses and expected substantial additional losses. Failure to obtain capital could force it to delay or reduce programs, relinquish technology rights, or threaten its ability to continue as a going concern. Additional equity could dilute shareholders.
- Development and manufacturing risks: Preclinical results may not translate to people; regulatory review, clinical trials, and manufacturing scale-up are lengthy and uncertain. The company relied on a single source for clinical-grade donor livers and had applied for an FDA waiver to combine cells from two donors.
- Other disclosed matters: The San Diego laboratory had no redundant facility. The company extended its main facility lease to August 2024; reported operating lease commitments were $6.273M. It reported no material legal proceedings or off-balance-sheet arrangements. In the period after year-end through filing, it sold 6,087,382 shares through its ATM facility for about $5.0M net proceeds.
- Reporting and controls: The auditor issued unqualified opinions on the financial statements and internal control over financial reporting; management also concluded controls were effective. Adoption of Topic 606 did not materially affect the financial statements.
Important facts investors should verify
- Whether subsequent animal studies demonstrate durable liver-tissue function and support an IND, given the May 2019 findings and the planned work into 2020.
- Current cash, operating cash burn, remaining ATM capacity, and the timing and terms of any additional financing; the filing’s runway statement was based on the operating plan at filing.
- Revenue composition and customer demand, particularly the decline in service and collaboration revenue and the contribution from Samsara cell sales.
- Share-count dilution: 124.015M common shares were outstanding at March 31, 2019, with additional equity awards and reserved shares; the company also issued about $5.0M of ATM shares after year-end.
- Regulatory status of the two-donor waiver, clinical-grade liver supply, manufacturing optimization, and the lease-related obligations.